Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?

European Urology, Supplements

Volumn 7, Issue 5, 2008, Pages 422-425

  Catto, James W F ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; PSA; Urinary markers

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; COST CONTROL; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENDOSCOPIC SURGERY; HUMAN; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 44549086516     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.12.005     Document Type: Review

References (30)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
2. Messing E.M., Young T.B., Hunt V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (1995) 387-396 discussion 96-7
3. Hall R.R., Parmar M.K., Richards A.B., and Smith P.H. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 308 (1994) 257-260
4. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
5. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
6. Lachaine J., Valiquette L., and Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 7 (2000) 974-980
7. Zippe C., Pandrangi L., and Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161 (1999) 62-65
8. Wilson J.M.G., and Junger G. Principles and practice of screening for disease (1968), World Health Organization, Geneva, Switzerland
9. Britton J.P., Dowell A.C., and Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ 299 (1989) 1010-1012
10. Mayfield M.P., and Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 82 (1998) 825-828
11. Messing E.M., Young T.B., Hunt V.B., et al. Home screening for hematuria: results of a multiclinic study. J Urol 148 (1992) 289-292
12. Wallace D.M. Occupational urothelial cancer. Br J Urol 61 (1988) 175-182
13. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
14. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
15. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
16. van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911-1914
17. Zhao J., Richter J., Wagner U., et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 59 (1999) 4658-4661
18. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., and Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
19. Lokeshwar V.B., and Soloway M.S. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 165 (2001) 1067-1077
20. van Rhijn B.W., Lurkin I., Chopin D.K., et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9 (2003) 257-263
21. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23 (2005) 2903-2910
22. Yates D.R., Rehman I., Abbod M.F., et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 13 (2007) 2046-2053
23. Hovey R.M., Chu L., Balazs M., et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58 (1998) 3555-3560
24. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 6 Suppl 1 (2005) 35-63
25. Grossman H.B., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
26. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
27. Gutman S., and Kessler L.G. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 6 (2006) 565-571
28. Maruvada P., and Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 15 (2006) 1078-1082
29. Lotan Y., and Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 167 (2002) 75-79
30. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246